Konstantinos Elenitoba-Johnson

Konstantinos Elenitoba-Johnson is a molecular pathologist and cancer biologist who has contributed to understanding BET bromodomain inhibitors (BETi) including JQ1 and its analogs as epigenetic therapies that suppress MYC-driven oncogene programs and modulate PD-L1 expression, providing a mechanistic rationale for BETi+PD-1 inhibitor combinations. His laboratory studies transcriptional dependencies in hematologic malignancies and has characterized how BRD4 inhibition can reprogram the tumor microenvironment to enhance immunotherapy efficacy, particularly in lymphoma and AML.